Experimental: Combination BDC-3042 plus pembrolizumab
Escalating doses followed by expansion targeting advanced malignancies
Drug: BDC-3042
Dectin-2 agonist antibody
Drug: Pembrolizumab
Drug which blocks checkpoint proteins from binding with their partner proteins, allowing T cells to kill cancer cells
Other Names:
- Keytruda
- Immune checkpoint inhibitor
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
